Gold Nanoparticle-Modified Molecularly Imprinted Polymer-Coated Pencil Graphite Electrodes for Electrochemical Detection of Bisphenol A.

The sensitive Bisphenol A (BPA) detection by an electrochemical sensor based on gold nanoparticle-doped molecularly imprinted polymer was successfully improved. This study describes the development of a method for BPA detection in both aqueous solution and real water samples using N-methacroyl-(L)-cysteine methyl ester and N-methacryloyl-(L)-phenylalanine methyl ester coated pencil graphite electrodes modified with AuNPs by differential pulse voltammetry (DPV). Importantly, AuNPs, which increase the electroactivity, were used to increase the surface area of a BPA-imprinted pencil graphite electrode (MIP PGE) sensor.

Development of Molecularly Imprinted Magnetic Amino Acid-Based Nanoparticles for Voltammetric Analysis of Lead Ions in Honey.

Lead (Pb) is a hazardous metal that poses a significant threat to both the environment and human health. The presence of Pb in food products such as honey can pose a significant risk to human health and is therefore important to detect and monitor. In this study, we propose a voltammetric detection method using molecularly imprinted polymer (MIP) electrodes to detect Pb (II) ions in honey.

Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.

The solute carrier organic anion transporter family member 1B1 () encodes the organic anion-transporting polypeptide 1B1 (OATP1B1 protein) that transports statins to liver cells. Common genetic variants in , such as *5, cause altered systemic exposure to statins and therefore affect statin outcomes, with potential pharmacogenetic applications; yet, evidence is inconclusive. We studied common and rare variants in up to 64,000 patients from UK Biobank prescribed simvastatin or atorvastatin, combining whole-exome sequencing data with up to 25-year routine clinical records.

Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone.

Pharmacogenetic variants are associated with clinical outcomes during Calcium Channel Blocker (CCB) treatment, yet whether the effects are modified by genetically predicted clinical risk factors is unknown. We analyzed 32,000 UK Biobank participants treated with dihydropiridine CCBs (mean 5.9 years), including 23 pharmacogenetic variants, and calculated polygenic scores for systolic and diastolic blood pressures, body fat mass, and other patient characteristics.